PI3Kα inhibitor · small molecule
serabelisib
0 active trials across 3 of our biomarkers, targeting PI3Kα. Not approved for any biomarker on marked.bio yet.
Also known as TAK-117, MLN1117, INK1117.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| KRAS G12C | 0 | 1 | – |
| KRAS G12D | 0 | 1 | – |
| PIK3CA activating mutation | 0 | 2 | – |
Trials
0 of 2 trials shown
-
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
serabelisibCanagliflozin 300mg
…b in Combination With Canagliflozin in Patients With Advanced Solid Tumors With PIK3CA or KRAS Mutations
KRAS G12CKRAS G12DPIK3CA activating mutationBreast Cancer, Endometrial Cancer, Lung Cancer, Colo-rectal Cancer
-
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
serabelisibnab-paclitaxel
Tumor must harbor an activating mutation in the PIK3CA gene with or without PTEN loss, either previously documented or determined during screeni…
PIK3CA activating mutationAdvanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
No trials match these filters.